港股开盘，恒生指数低开0.77%，恒生科技指数低开0.58%。药明康德（603259）港股低开超4%，消息 面上，药明康德拟折让约6.90%配售7380万股新H股，净筹约76.5亿港元。 ...

Focus Events - The 20th Central Committee's Fourth Plenary Session will be held in October in Beijing, focusing on the report of work and the formulation of the 15th Five-Year Plan for national economic and social development [1] Macro News - The average interest rate for newly issued commercial housing loans in Q2 2025 is 3.09% [18] - The Ministry of Agriculture and Rural Affairs is guiding the orderly elimination of low-yield dairy cows and enhancing support for large-scale breeding enterprises [18] Company Focus - Feilong Co., Ltd. is expanding into the robotics industry, collaborating with several vehicle manufacturers on product development [20] - Yonghui Supermarket plans to raise up to 3.992 billion yuan through a private placement for store upgrades and logistics improvements [21] - WuXi AppTec is issuing new H-shares at a price of 104.27 HKD per share, aiming to raise approximately 7.7 billion HKD [23] - China Shipbuilding Emergency Response received a warning and a fine of 4 million yuan for information disclosure violations, with its stock being marked as ST [25] - Hongxiang Co., Ltd.'s actual controller has been released on bail [27] - A stock of Upwind New Materials has been suspended for review after a 1083.42% increase in price over 16 trading days [29] - CATL reported a net profit of 30.5 billion yuan for the first half of 2025, a 33% year-on-year increase [31] - XGIMI expects a 2062.33% increase in net profit for the first half of 2025 [33] - Zhiwei Intelligent reported a net profit of 102 million yuan for the first half of 2025, an 80.08% increase [34] - Jinhai Biological reported a net profit of 138 million yuan for the first half of 2025, a 51.52% increase [34] - Lideman is planning to acquire control of Xiansheng Xiangrui [36] - San Chao New Materials is planning a change in control, with stock suspension starting July 31 [36] - Digital Certification will change its controlling shareholder to Beijing Data Group [37] - Jin Orange is planning to acquire 55% of Samit [37] - Taotao Vehicle announced a strategic cooperation agreement with Yushu Technology for market expansion in robotics [38] - China State Construction recently secured 9 major projects totaling 28.33 billion yuan [40] - Yangtze Power plans to invest approximately 26.6 billion yuan in the Gezhouba shipping capacity expansion project [42] - Changying Precision has established partnerships with several leading humanoid robot brands [44]

此次配售股数拟定为7380万股H股，配售价为104.27港元/股，募资净额约为76.5亿港元，约90%将用于 全球布局和产能建设，约10%将用于补充一般运营资金。 人民财讯7月31日电，药明康德（603259）7月31日早间公告，公司拟根据2024年年度股东大会审议通过 的《关于给予董事会增发公司A股和/或H股股份一般性授权的议案》项下股东大会对董事会增发股份的 授权，新增发行境外上市外资股（H股）。 ...

北京商报讯（记者 丁宁）7月31日早间，药明康德（603259）公告称，公司拟根据2024年年度股东大会 审议通过的《关于给予董事会增发公司A股和/或H股股份一般性授权的议案》 项下股东大会对董事会增 发股份的授权， 新增发行境外上市外资股 （H股） 。 公告显示，本次发行的募集资金净额约76.5亿港元，其中约90%将用于全球布局和产能建设，约10%将 用于补充一般运营资金。 ...

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit, driven by the rapid development of core businesses [1][4]. Revenue Performance - In H1 2025, the company achieved revenue of 20.799 billion yuan, representing a year-on-year increase of 20.64% [2]. - The chemical business generated revenue of 16.301 billion yuan (+33.51%), while the testing and biological businesses reported revenues of 2.689 billion yuan (-1.20%) and 1.252 billion yuan (+7.07%), respectively [2]. Profit Performance - The company reported a net profit attributable to shareholders of 8.561 billion yuan in H1 2025, reflecting a year-on-year growth of 101.92% [3]. Business Development - The small molecule D&M business showed strong growth, with a project pipeline expanding rapidly. In H1 2025, the pipeline added 412 new molecules, with 76 commercial projects and 84 clinical phase III projects [5]. - The company’s small molecule API production facilities successfully passed FDA inspections, with total reactor volume expected to exceed 4,000 kL by the end of 2025 [5]. TIDES Business Growth - The TIDES business experienced robust growth, with revenue reaching 5.03 billion yuan (+141.6%) in H1 2025. The backlog of orders increased by 48.8% year-on-year, maintaining a high growth trend [6]. - The company is actively expanding its peptide production capacity, with total reactor volume expected to exceed 100,000 liters by the end of 2025 [6]. Investment Outlook - The company is projected to achieve net profits of 13.952 billion yuan, 14.336 billion yuan, and 15.985 billion yuan for the years 2025 to 2027, representing year-on-year growth rates of 47.6%, 2.8%, and 11.5%, respectively [7]. - A price-to-earnings ratio of 25 is anticipated for 2025, with an estimated earnings per share of 4.86 yuan, leading to a target price of 121.50 yuan per share, with a buy-A investment rating [7].

本次配售股数拟定为7380万股H股，配售价格拟定为104.27港元/股，募集资金在扣除发行相关费用后的 净额约为76.5亿港元，将用于：(1)约90%将用于全球布局和产能建设;(2)约10%将用于补充一般运营资 金。 药明康德（603259）(603259.SH)发布公告，为满足公司加速推进全球布局和产能建设，驱动公司长期 发展，高效极致服务客户，最终实现"让天下没有难做的药，没有难治的病"，造福全球病患，经公司第 三届董事会第二十四次会议审议批准，公司拟根据2024年年度股东大会审议通过的《关于给予董事会增 发公司A股和/或H股股份一般性授权的议案》项下股东大会对董事会增发股份的授权，新增发行境外上 市外资股(H股)。 ...

本次配售股数拟定为7380万股H股，配售价格拟定为104.27港元/股，募集资金在扣除发行相关费用后的 净额约为76.5亿港元，将用于：(1)约90%将用于全球布局和产能建设;(2)约10%将用于补充一般运营资 金。 智通财经APP讯，药明康德(603259.SH)发布公告，为满足公司加速推进全球布局和产能建设，驱动公 司长期发展，高效极致服务客户，最终实现"让天下没有难做的药，没有难治的病"，造福全球病患，经 公司第三届董事会第二十四次会议审议批准，公司拟根据2024年年度股东大会审议通过的《关于给予董 事会增发公司A股和/或H股股份一般性授权的议案》项下股东大会对董事会增发股份的授权，新增发行 境外上市外资股(H股)。 ...

配售的募集资金净额(经扣除相关成本及费用、佣金及交易征费)预计约为76.5亿港元(按每股配售股份净 价约103.62港元计算)，将按以下方式投入使用：约90%将用于加速推进全球布局和产能建设;及约10% 将用于一般公司用途。 药明康德（603259）(02359)发布公告，董事会欣然宣布于2025年7月31日，公司与配售代理订立配售协 议，据此，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并 尽力促使承配人按照配售协议所载条款及条件，按每股配售股份配售价合共认购7380万股新H股。 配售股份数目占紧随完成后经发行配售股份扩大后的已发行H股总数及已发行股份总数约16.01%及 2.51%(假设于本公告日期至完成期间所有配售股份均获认购，且除公司发行配售股份外，已发行股份总 数不会变动)。配售价每股配售股份104.27港元较：2025年7月30日(即紧接配售协议日期前最后一个交易 日)香港联交所所报收市价每股H股112.00港元折让约6.90%。 ...

药明康德在港交所公告，7月31日，公司与配售代理订立配售协议，据此，公司同意委任配售代理而配 售代理各自同意出任公司代理，并尽力促使若干承配人按照配售协议所载条款及条件，按每股配售股份 104.27港元合共认购公司根据一般授权将发行的73,800,000股新H股。假设所有配售股份获悉数认购，配 售的募集资金总额预计将约为77.0亿港元。配售的募集资金净额中约90%将用于加速推进全球布局和产 能建设，约10%将用于一般公司用途。 ...

配售股份数目占紧随完成后经发行配售股份扩大后的已发行H股总数及已发行股份总数约16.01%及 2.51%(假设于本公告日期至完成期间所有配售股份均获认购，且除公司发行配售股份外，已发行股份总 数不会变动)。配售价每股配售股份104.27港元较：2025年7月30日(即紧接配售协议日期前最后一个交易 日)香港联交所所报收市价每股H股112.00港元折让约6.90%。 配售的募集资金净额(经扣除相关成本及费用、佣金及交易征费)预计约为76.5亿港元(按每股配售股份净 价约103.62港元计算)，将按以下方式投入使用：约90%将用于加速推进全球布局和产能建设;及约10% 将用于一般公司用途。 智通财经APP讯，药明康德(02359)发布公告，董事会欣然宣布于2025年7月31日，公司与配售代理订立 配售协议，据此，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公司代 理，并尽力促使承配人按照配售协议所载条款及条件，按每股配售股份配售价合共认购7380万股新H 股。 ...